Literature DB >> 28373334

Evaluating The Role Of Payment Policy In Driving Vertical Integration In The Oncology Market.

Abby Alpert1, Helen Hsi2, Mireille Jacobson3.   

Abstract

The health care industry has experienced massive consolidation over the past decade. Much of the consolidation has been vertical (with hospitals acquiring physician practices) instead of horizontal (with physician practices or hospitals merging with similar entities). We documented the increase in vertical integration in the market for cancer care in the period 2003-15, finding that the rate of hospital or health system ownership of practices doubled from about 30 percent to about 60 percent. The two most commonly cited explanations for this consolidation are a 2005 Medicare Part B payment reform that dramatically reduced reimbursement for chemotherapy drugs, and the expansion of hospital eligibility for the 340B Drug Discount Program under the Affordable Care Act (ACA). To evaluate the evidence for these explanations, we used difference-in-differences methods to assess whether consolidation increased more in areas with greater exposure to each policy than in areas with less exposure. We found little evidence that either policy contributed to vertical integration. Rather, increased consolidation in the market for cancer care may be part of a broader post-ACA trend toward integrated health care systems. Project HOPE—The People-to-People Health Foundation, Inc.

Entities:  

Keywords:  Consolidation; oncology

Mesh:

Year:  2017        PMID: 28373334     DOI: 10.1377/hlthaff.2016.0830

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  11 in total

1.  The impact of integration on outpatient chemotherapy use and spending in Medicare.

Authors:  Jeah Jung; Roger Feldman; Yamini Kalidindi
Journal:  Health Econ       Date:  2019-01-29       Impact factor: 3.046

Review 2.  Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment.

Authors:  Scott F Huntington
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

3.  Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare.

Authors:  Jeah Jung; Wendy Y Xu; Yamini Kalidindi
Journal:  Health Serv Res       Date:  2018-01-22       Impact factor: 3.402

4.  Vertical Integration Versus Physician Owners: Trends in Practice Structure Among Breast Cancer Surgeons.

Authors:  Jean M Mitchell; Thomas DeLeire
Journal:  Med Care       Date:  2022-03-01       Impact factor: 2.983

5.  The Influence of Practice Structure on Urologists' Treatment of Men With Low-Risk Prostate Cancer.

Authors:  Jean M Mitchell; Carole Roan Gresenz
Journal:  Med Care       Date:  2022-07-26       Impact factor: 3.178

6.  Relationship between initiation of 340B participation and hospital safety-net engagement.

Authors:  Sayeh S Nikpay; Melinda B Buntin; Rena M Conti
Journal:  Health Serv Res       Date:  2020-04       Impact factor: 3.402

7.  Association of Clinician Health System Affiliation With Outpatient Performance Ratings in the Medicare Merit-based Incentive Payment System.

Authors:  Kenton J Johnston; Timothy L Wiemken; Jason M Hockenberry; Jose F Figueroa; Karen E Joynt Maddox
Journal:  JAMA       Date:  2020-09-08       Impact factor: 56.272

8.  Assessing the Quality of SK&A's Office-Based Physician Database for Identifying Oncologists.

Authors:  Samuel Valdez; Mireille Jacobson
Journal:  Med Care Res Rev       Date:  2021-05-24       Impact factor: 2.971

9.  Do Medicare's Facility Fees Incentivize Hospitals to Vertically Integrate with Oncologists?

Authors:  Samuel Valdez
Journal:  Inquiry       Date:  2021 Jan-Dec       Impact factor: 1.730

10.  Influences of Physical Layout and Space on Patient Safety and Communication in Ambulatory Oncology Practices: A Multisite, Mixed Method Investigation.

Authors:  Alex Fauer; Nathan Wright; Megan Lafferty; Molly Harrod; Milisa Manojlovich; Christopher R Friese
Journal:  HERD       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.